Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01094496 · ClinicalTrials.gov registry record · Phase 2
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
A Phase 2 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01094496: Clinical Trial Phase 2 study, sponsored by Celldex Therapeutics.
NCT01094496 is a Phase 2 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01094496, a Phase 2 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The major purpose of this study is to examine the anti-tumor activity of the CDX-1307 vaccine regimen when it is given before and after bladder cancer surgery. The study will also provide information about the safety of the vaccine regimen when given in combination with chemotherapy, and how it affects the immune systems.
Primary Outcome
The 2-year recurrence-free survival rate will be estimated based on the proportion of patients who are classified as alive and without documented disease recurrence at this time point.
Interventions
- DRUG Chemotherapy
- BIOLOGICAL CDX-1307 Vaccine Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Why NCT01094496 stopped before completion
NCT01094496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Chemotherapy is the first listed.
NCT01094496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01094496 about?
NCT01094496 is a clinical study titled "A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)". The major purpose of this study is to examine the anti-tumor activity of the CDX-1307 vaccine regimen when it is given before and after bladder cancer surgery. The study will also provide information about the safety of the vaccine regimen when given in combination with chemotherapy, and how it affe...
What is the current status of trial NCT01094496?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2010-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01094496?
The interventions under investigation include: Chemotherapy (DRUG), CDX-1307 Vaccine Regimen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01094496?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01094496's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia